Somapacitan
- Generic Name
- Somapacitan
- Brand Names
- Sogroya
- Drug Type
- Biotech
- CAS Number
- 1338578-34-9
- Unique Ingredient Identifier
- 8FOJ430U94
Overview
Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency. This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020.
Background
Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency. This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020.
Indication
Somapacitan is indicated as a replacement for growth hormone in adult patients with growth hormone deficiency.
Associated Conditions
- Human Growth Hormone Deficiency
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.